Our drug candidate
p-HTMI is currently being developed for use during glioma brain tumor surgery for detection and illumination of glioma stem cells. Emerging research suggests that failure to target glioma stem cells rather than the inability to remove tumors through surgery, radiation, or chemotherapy, explains the poor survival of malignant glioma patients. p-HTMI is intended to enable neurosurgeons to detect, and surgically remove, glioma stem cells during fluorescence-guided surgery.
p-HTMI is currently in pre-clinical phase and is expected to enter clinical phase 1 during 2027. Accordingly, p-HTMI is not commercially available.
For further information, please contact us by e-mail or by filling out this form.